- TRADE NAME: Rezurock (Kadmon)
- INDICATIONS: Chronic graft-versus-host disease. (A complication of allogenuc hematopoietic stem cell transplantation).
- SYNONYM: Belumosudil mesylate
- CLASS: Kinase inhibitor
- HALF-LIFE: 19 hours
- FDA APPROVAL DATE: 07/16/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A Inducers, Proton pump inhibitors - PREGNANCY: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 02/16/2024
